FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Tag: NASDAQ:GNMK

Sort
E.g., 2013-05-22
E.g., 2013-05-22
Enter a comma separated list of user names.

NPS Pharmaceuticals, Inc. (Nasdaq:NPSP) announced the randomization of the last patient in REPLACE, its Phase 3 registration study of NPSP558, a bioengineered form of human parathyroid hormone. REPLACE was a double-blind, placebo-controlled study evaluating the use of NPSP558 as hormone replacement therapy in adult patients with hypoparathyroidism.

ADVERTISE WITH US